This randomized phase III trial studies how well initial treatment with ipilimumab and nivolumab followed by dabrafenib and trametinib works and compares it to initial treatment with dabrafenib and trametinib followed by ipilimumab and nivolumab in treating patients with stage III-IV melanoma that contains a mutation known as v-raf murine sarcoma viral oncogene homolog B V600 (BRAFV600) and cannot be removed by surgery. Ipilimumab and nivolumab may block tumor growth by targeting certain cells. Dabrafenib and trametinib may block tumor growth by targeting the BRAFV600 gene. It is not yet known whether treating patients with ipilimumab and nivolumab followed by dabrafenib and trametinib is more effective than treatment with dabrafenib and trametinib followed by ipilimumab and nivolumab.
Contact site for start date.
Please contact ClinicalResearch@sutterhealth.org about Study EA6134.
View study details on ClinicalTrials.gov
MALE and FEMALE subjects, 18 y/o and older, with histological or cytological confirmation of melanoma that is metastatic or unresectable and clearly progressive. Patients must have BRAFV600E or BRAFV600K mutations. May have had prior systemic therapy in the adjuvant setting; patients may not have had any prior ipilimumab or BRAF inhibitors in the adjuvant setting.
June 01, 2018